205 related articles for article (PubMed ID: 33397120)
1. Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report.
Mulroy M; Ghafouri S; Sisk A; Ribas A; Goshtaseb R; Cherry G; Shen J
Immunotherapy; 2021 Mar; 13(4):283-288. PubMed ID: 33397120
[TBL] [Abstract][Full Text] [Related]
2. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use.
Min JW; Lim JU
Semin Oncol; 2022 Apr; 49(2):141-147. PubMed ID: 35264308
[TBL] [Abstract][Full Text] [Related]
4. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors and acute kidney injury.
Zhou P; Gao Y; Kong Z; Wang J; Si S; Han W; Li J; Lv Z; Wang R
Front Immunol; 2024; 15():1353339. PubMed ID: 38464524
[TBL] [Abstract][Full Text] [Related]
6. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
Escandon J; Peacock S; Trabolsi A; Thomas DB; Layka A; Lutzky J
J Immunother Cancer; 2017; 5():3. PubMed ID: 28105370
[TBL] [Abstract][Full Text] [Related]
7. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
Tabei A; Watanabe M; Ikeuchi H; Nakasatomi M; Sakairi T; Kaneko Y; Maeshima A; Kaira K; Hirato J; Nojima Y; Hiromura K
Intern Med; 2018 Nov; 57(21):3135-3139. PubMed ID: 29877267
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury from immune checkpoint inhibitor use.
Gordon L; Dokouhaki P; Hagel K; Prasad B
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653633
[TBL] [Abstract][Full Text] [Related]
9. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma.
Patel V; Elias R; Formella J; Schwartzman W; Christie A; Cai Q; Malladi V; Kapur P; Vazquez M; McKay R; Pedrosa I; Hannan R; Hammers H; Brugarolas J
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33139246
[TBL] [Abstract][Full Text] [Related]
10. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
11. Interstitial nephritis with pembrolizumab: A case report and review.
Peláez Bejarano A; Montero Pérez O; Inoriza Rueda A; Garrido Martínez MT
J Oncol Pharm Pract; 2021 Jun; 27(4):1046-1051. PubMed ID: 33040674
[TBL] [Abstract][Full Text] [Related]
12. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge.
Seethapathy H; Herrmann SM; Rashidi A
Semin Nephrol; 2022 Nov; 42(6):151346. PubMed ID: 37137187
[TBL] [Abstract][Full Text] [Related]
14. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis.
Fujioka H; Kakeshita K; Imamura T; Arisawa Y; Yokoyama S; Yamazaki H; Koike T; Minamisaka T; Hirabayashi K; Kinugawa K
Intern Med; 2024 Feb; 63(4):533-539. PubMed ID: 37380456
[TBL] [Abstract][Full Text] [Related]
16. Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab.
Shah N; Jacob J; Househ Z; Shiner E; Baird L; Soudy H
J Immunother Cancer; 2019 Sep; 7(1):247. PubMed ID: 31511075
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events.
Adam BA; Murakami N; Reid G; Du K; Jasim R; Boils CL; Bu L; Hill PD; Murray AG; Renaudin K; Roufosse C; Weins A; Wen K; Riella LV; Mengel M
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1376-1386. PubMed ID: 34244334
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
[TBL] [Abstract][Full Text] [Related]
19. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
20. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]